Anchored in work originally initiated and undertaken at Cornell (Bioregenerative Medicine and Surgery Lab) Fesarius Therapeutics, Inc. is an early stage biomedical company structured around development of an engineered skin replacement product using patented microsphere hydrogel technology. With the effort being to deliver superior healing outcomes for complex wounds, Fesarius Therapeutics' foundational scaffold technology - also licensed from Cornell University - offers the added advantage of improving patient lives and likely lowering the cost of related medical care. The expectation is that the firm's objective to have usable caability could be acheived in about five years.
